France Biobanking Market Overview, 2029

The biobanking sector in France is continuously expanding which is an important part of the country's healthcare and research infrastructure. Biobanks contain a variety of biological samples, including blood, tissues, cells, and DNA, together with relevant clinical and demographic information. The development of customized medicines, understanding the underlying causes of disease, and furthering medical research all depend on these instruments. In France, there are 2 types of biobank public and private. Public biobanks are usually associated with universities, hospitals, and research organizations, on the other hand private biobanks are primarily managed by biotechnology enterprises and pharmaceutical companies. Strict rules and regulations are in place to monitor biobanking activities in France, safeguard patient rights, encourage moral behaviour, and maintain data and privacy. The aim of European biobanking projects are to standardize biobanking practices and increase global cooperation. However, biobanks continue to have a major impact on healthcare and medical research. Sample quality, data management interoperability, and financing stability are some of the major issue that France is facing. However, the additional investments in infrastructure, technologies, and workforce developments which address these issues. Biobanks have the chance to take advantage of cutting-edge technology like big data and artificial intelligence (AI). A wide range of research projects, and collaboration between industry, healthcare, and university define the French biobanking market. French biobanks have the potential to significantly contribute to the betterment of biomedical research and the enhancement of patient care by embracing chances for innovation and tackling significant problems.

According to the research report, " France Biobanking Market Outlook, 2029," published by Bonafide Research, the France Biobanking market is anticipated to add to more than USD 1.4 Billion by 2024–29. The major developments in biobanking industry in France can be seen as the shift towards personalized medication, which aims to give medical treatments to individual patients based on their genetic other factors, has fueled the demand for high-quality biological samples and associated data. Biobanks play a crucial role in supporting personalized medicine initiatives by providing researchers and clinicians with access to diverse collections of samples for biomarker discovery, disease modeling, and treatment optimization. In France, product types like as consumables, laboratory information systems, and equipment are the basis for segmentation. The several types of equipment used in biobanking sector which refers to a variety of tools and technology used in biological sample collection, processing, storage, and analysis. The consumable describes the throwaway tools used in sample collection, storage, and analysis biobanking procedures. Software programs known as LIMS are made to track and manage sample data, workflows in laboratories, and related metadata. Stakeholders are better able to comprehend the unique requirements and preferences of customers within each category based on the type of product. Additionally, it enables businesses to more successfully target various market segments by customizing their product offerings and marketing plans. It also makes it possible for academics and decision-makers to assess patterns and advancements in every product area and spot chances for innovation.

Make this report your own

Have queries/questions regarding a report?

Take advantage of intelligence tailored to your business objective

Ask an Expert

Manmayi Raval

Research Consultant

Biological samples and related data are gathered, stored, and managed as part of biobanking and repository services. The quality, integrity, and dependability of biological samples and related data kept in biobanks are guaranteed by validation and qualification services. A variety of tasks pertaining to sample preparation, analysis, and characterisation are included in lab processing services. In order to preserve sample integrity and stability, cold chain logistics services make sure that biological samples are handled, transported, and stored properly under temperature control. In order to satisfy the changing needs of the biobanking sector, it also helps service providers to distinguish their products and services and customize their service portfolios. It also makes resource allocation and strategic planning easier.

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

There are two types of biobanks ,Either actual or virtual biobanks serve as the foundation for segmentation in France. Physical repositories, such as blood banks, tissue banks, cell banks, and DNA banks, are used to store biological samples and related data in tangible form. For use in treatment development, medical research, and diagnostics, these biobanks preserve collections of samples drawn from people, patients, and communities. Hospitals, research institutes, and academic centers are examples of organizations that may have physical biobanks located in one site or spread across several. In contrast to physical specimen storage, virtual biobanks—also referred to as registry-based biobanks or data-driven biobanks—store biological sample information and related data in digital or electronic forms. In France Biobanking is important for the advancement of biomedical research and healthcare. Biobanks are important sector for medicine developments and academic studies as they store samples of life such as tissues, blood, and DNA. These samples are important for finding the causes of diseases and creating new therapeutic targets. These biobanks speed up medical research and improve the efficacy of clinical trials by facilitating partnerships among universities, pharmaceutical corporations, and medical professionals. The several projects in France are going on for personalised healthcare benefit greatly from biobanking in the therapeutics domain. Biobanks let medical personnel better treat specific patients by keeping genetic and molecular data with clinical information. This helps to minimise side effects and improve therapeutic outcomes. Biobanks provide physicians with superior specimens for molecular testing in clinical diagnostics, assisting in the timely identification and precise diagnosis of a range of illnesses. Not only these biobanking in France facilitates various other research projects, including population-based studies, environmental health evaluations, and forensic inquiries, highlighting its diverse function in promoting scientific understanding and public health campaigns. Considered in this report • Historic year: 2018 • Base year: 2023 • Estimated year: 2024 • Forecast year: 2029 Aspects covered in this report • Biobanking market Outlook with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Product Type • Equipment • Consumables • Laboratory Information Systems By Service Type • Biobanking and Repository • Validation/Qualification • Lab Processing • Cold Chain Logistic • Others By Biospecimen Type • Human Tissues • Stem Cells • Organs • Others By Biobank • Physical Biobanks • Virtual Biobanks By Application • Drug Discovery and Clinical Research • Therapeutics • Clinical Diagnostics • Others By Type of Biobank • Population-based Biobanks • Disease-oriented Biobanks By Ownership • National/regional agency • Non-Profit Organization • Universities • Private Organization By Storage • Manual Storage • Automated Storage The approach of the report: This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Biobanking industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.